A Randomized, Open-Label, Parallel-Design Trial. Glycemia Optimization Treatment: Safety of Glucose Control Using Dosing Algorithms With Lantus (Insulin Glargine [rDNA Origin[) in Adult Individuals With Type 2 Diabetes.

Trial Profile

A Randomized, Open-Label, Parallel-Design Trial. Glycemia Optimization Treatment: Safety of Glucose Control Using Dosing Algorithms With Lantus (Insulin Glargine [rDNA Origin[) in Adult Individuals With Type 2 Diabetes.

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Jul 2009

At a glance

  • Drugs Insulin glargine (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 22 Jul 2009 Planned end date changed from Feb 2005 to Mar 2005 as reported by ClinicalTrials.gov.
    • 22 Jul 2009 Actual patient number (5062) added as reported by ClinicalTrials.gov.
    • 26 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top